Skip to main content

Table 7 Characteristics of studies included based on treatment regimens: PARPi alone

From: Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

 

Affiliation

Type of study

Stage of disease

Nº of BRCA1/2 mutated TNBC patients

pCR

Neoadjuvant treatment

Litton 2020 [15]

USA

Pilot study

I-III

15

7

T

Eikesdal 2019

PETREMAC trial [48]

Norway

Phase II Trial

II-III

4

3

O

  1. pCR Pathological complete response, T Talazoparib, O Olaparib
Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287